Member Login | Links

Society of Utah Medical Oncologists

Society of Utah Medical Oncologists

  • About Us
  • Membership
  • Practice Issues
  • News
    • All News
    • ACCC
    • ASCO
    • ASCO Alert
    • CMS Update
    • FDA
    • FDA Approval
    • Health Care
    • Medicare
    • NCCN Flash Updates
    • News Article
    • Oplinc
    • Patient Assistance
    • PQRI Standards for Oncology
    • Recall
    • United Healthcare
  • Legislation
  • Directory
  • Contact

Education • Collaboration • Advocacy

Improving the quality of patient care.

Advocating for patients & their families.

Connecting & uniting oncology in Utah.

Diamond Corporate MemberDiamond Corporate MemberDiamond Corporate MemberDiamond Corporate MemberDiamond Corporate MemberDiamond Corporate MemberPlatinum Corporate MemberPlatinum Corporate MemberPlatinum Corporate MemberPlatinum Corporate MemberPlatinum Corporate MemberGold Corporate MemberGold Corporate MemberSilver Corporate MemberSilver Corporate MemberSilver Corporate MemberBronze Corporate MemberBronze Corporate MemberBronze Corporate MemberBronze Corporate MemberBronze Corporate MemberBronze Corporate MemberBronze Corporate MemberBronze Corporate Member

Membership

signup

Education & Events

  • Your Practice and the Medicare Patient: Considerations for Access

    Online Presentation Sponsored by Genentech Presented by William Koch, Administrative Director Yvette Cordova, Practice Administrator GENENTECH WEBCAST Wednesday, April 04, 2018 Event Code: MF009531 Log-In Time: 12:00pm EST Event Code: MF009532 Log-In Time: 12pm CST Event Code: MF009533 Log-In Time: … Continued

  • Save the Date – Fall Clinical Meeting

    Sumo Fall Clinical meeting September 21-22, 2018 Hyatt Centric Park City 3551 N. Escala Court, Park City, UT 84098 435-940-1234 Registration information coming soon! Questions? E-Mail: [email protected] [email protected] Phone: 801-736-0086

All Education & Events >>

News

  • thrombocytopenia

    Food and Drug Administration approved avatrombopag (Doptelet, AkaRx Inc.) for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure. Approval was based on two international, identically designed, randomized, double-blind, placebo-controlled trials, ADAPT-1 and ADAPT-2. Patients (n=430) with … Continued

  • Retacrit

    Food and Drug Administration approved Retacrit (epoetin alfa-epbx, Hospira Inc., a subsidiary of Pfizer Inc.) as a biosimilar to Epogen/Procrit (epoetin alfa, Amgen Inc.) for the treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis and … Continued

All News >>

Polls

  • This field is for validation purposes and should be left unchanged.
Twitter Facebook Connect with us!

Privacy Policy | Terms of Use

Copyright 2008-2018© Society of Utah Medical Oncologists.
All rights reserved.
Phone: 801-736-0086